How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lorlatinib

Marketing authorisation indication

2.1

Lorlatinib (Lorviqua) is indicated for the 'treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor or whose disease has progressed after prior treatment with an ALK inhibitor.'

Price

2.3

The list price of 30 lorlatinib 100-mg tablets and 90 lorlatinib 25‑mg tablets is £5,283 (excluding VAT; BNF online; accessed March 2025).

2.4

The company has a commercial arrangement for lorlatinib as a second-line treatment. This makes lorlatinib available to the NHS with a discount. The company proposed a new discount for lorlatinib for this evaluation. This new discount would have applied to both first-line and second-line lorlatinib had it been recommended at first line. The size of the discount is commercial in confidence.